Empowering Oncology Decisions

DiagnoCure is a life sciences company commercializing high-value cancer diagnostic tests and lab services that increase clinician and patient confidence in making critical treatment decisions.

GCC Tests for Colorectal Cancer

DiagnoCure has acquired diagnostic rights to the GCC marker with utility in colorectal cancer and intends to launch the first GCC test in 2008.

Previstage™ GCC Colorectal Staging Test »

GCC colorectal cancer monitoring test »

PCA3 Molecular Marker

The PCA3 test for prostate cancer is now available through laboratories in the U.S. using PCA3 analyte specific reagents (ASR) from Gen-Probe, and in Europe as the CE-marked PROGENSA™ PCA3 in vitro assay.

Special Media Coverage on PCA3 »

More on PCA3 »

External site on PCA3, Ismar Healthcare »

Shc Proteins for Breast, Colon and
other Cancers

On August 2007, DiagnoCure acquired lead proprietary prognostic tests with applications in five tumor types, including breast and colon.

Research on Shc proteins »

INVESTORS

1.89
-0.06
Open: 2.00
$CAN.
Quotes are delayed.
 

Latest News

Upcoming Events

May 30 - June 3, 2008
ASCO Annual '08 Meeting
Chicago, IL, USA

June 7 - 11, 2008
American Society of Colon & Rectal Surgeons Annual Meeting
Boston, MA, USA

September 25 - 28, 2008
College of American Pathologists Annual Meeting
San Diego, CA, USA

Calendar »